So many choices, so what's a consumer to do?: A commentary on "Effect of chromium niacinate and chromium picolinate supplementation on lipid peroxidation, TNF-α, IL-6, CRP, glycated hemoglobin, triglycerides, and cholesterol levels in blood of streptozotocin-treated diabetic rats"

Free Radical Biology and Medicine

Volumn 43, Issue 8, 2007, Pages 1121-1123

  Vinson, Joe A ^a  

^a UNIVERSITY OF SCRANTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL; CHROMIUM DERIVATIVE; CHROMIUM NIACINATE; CHROMIUM PICOLINATE; GLYCOSYLATED HEMOGLOBIN; INTERLEUKIN 6; SULFONYLUREA; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; CHOLESTEROL BLOOD LEVEL; COMBINATION CHEMOTHERAPY; DRUG DOSE REDUCTION; FOOD AND DRUG ADMINISTRATION; HUMAN; INSULIN SENSITIVITY; LIFESTYLE; LIPID PEROXIDATION; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUTRITION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; STREPTOZOCIN DIABETES; SUPPLEMENTATION;

RATTUS;

EID: 34548476753     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2007.06.029     Document Type: Note

References (26)

1. Wild S., Roglic G., Green A., Sicree R., and King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27 (2004) 1047-1053
2. Centers for Disease Control and Prevention. National diabetes fact sheet: general information and national estimates on diabetes in the United States, 2003. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention; 2004.
3. Jay D., Hitomi H., and Griendling K.K. Oxidative stress and diabetic cardiovascular complications. Free Radic. Biol. Med. 40 (2006) 183-189
4. Riddle M.C. Glycemic management of type 2 diabetes: an emerging strategy with oral agents, insulins, and combinations. Endocrinol. Metab. Clin. N. Am. 34 (2005) 77-98
5. Gibson J.E., and Taylor D.A. Can claims, misleading information, and manufacturing issues regarding dietary supplements be improved in the United States?. J. Pharmacol. Exp. Ther. 314 (2005) 939-944
6. Neuhouser M.L. Dietary supplement use by American women: challenges in assessing patterns of use, motives and costs. J. Nutr. 133 (2003) 1992S-1996S
7. Nielsen F. Controversial chromium; does the superstar mineral of the Mountebanks receive appropriate attention from clinicians and nutritionists. Nutr. Today 31 (2005) 2226-2233
8. Mirasol F. Chromium picolinate market sees robust growth and high demand. Chem. Mark. Rep. 257 (2000)
9. Speetjens J.K., Collins R.A., Vincent J.B., and Woski S.A. The nutritional supplement chromium(III) tris(picolinate) cleaves DNA. Chem. Res. Toxicol. 12 (1999) 483-487
10. Sun Y., Ramirez J., Woski S.A., and Vincent J.B. The binding of trivalent chromium to low-molecular-weight chromium-binding substance (LMWCr) and the transfer of chromium from transferrin and chromium picolinate to LMWCr. J. Biol. Inorg. Chem. 5 (2000) 129-136
11. Shara M., Kincaid A.E., Limpach A.L., Sandstrom R., Barrett L., Norton N., Bramble J.D., Yasmin T., Tran J., Chatterjee A., Bagchi M., and Bagchi D. Long-term safety evaluation of a novel oxygen-coordinated niacin-bound chromium (III) complex. J. Inorg. Biochem. 101 (2007) 1059-1069
12. Anderson R.A., Bryden N.A., and Polansky M.M. Lack of toxicity of chromium chloride and chromium picolinate in rats. J. Am. Coll. Nutr. 16 (1997) 273-279
13. Trumbo P., Yates A.A., Schlicker S., and Poos M. Dietary references intakes: vitamin A, vitamin K, arsenic, boron, chromium, copper, iodine, iron, manganese, molybdenum, nickel, silicon, vanadium, and zinc. J. Am. Diet Assoc. 101 (2001) 294-301
14. Schwarz K., and Mertz W. Chromium (III) and the glucose tolerance factor. Arch. Biochem. Biophys. 85 (1959) 294-295
15. Vincent J.B. Recent advances in the nutritional biochemistry of trivalent chromium. Proc. Nutr. Soc. 63 (2004) 41-47
16. Vincent J.B. The biochemistry of chromium. J. Nutr. 130 (2000) 715-814
17. Anderson R.A., and Kozlovsky A.S. Chromium intake, absorption and excretion of subjects consuming self-selected diets. Am. J. Clin. Nutr. 41 (1985) 1177-1183
18. Disilvestro R.A., and Dy E. Comparison of acute absorption of commercially available chromium supplements. J. Trace Elem. Med. Biol. 21 (2007) 120-124
19. Vinson J.A., and Hsiao K.H. Comparative effect of various forms of chromium on serum glucose: an assay for biologically active chromium. Nutr. Rep. Int. 32 (1985) 1-7
20. Jain, S. L.; Rains, J. L.; Croad, J. L. Effect of chromium nicinate and chromium picolinate supplementation on lipid peroxidation, TNF-α, IL-6, CRP, glycated hemoglobin, and cholesterol levels in blood of streptozotocin-treated diabetic rats. Free Radic. Biol. Med.
21. Trumbo P.R., and Ellwood K.C. Chromium picolinate intake and risk of type 2 diabetes: an evidence-based review by the United States Food and Drug Administration. Nutr. Rev. 64 (2006) 357-363
22. Cefalu W.T., Bell-Farrow A.D., and Stegner J. Effect of chromium picolinate on insulin sensitivity in vivo. J. Trace Elem. Exp. Med. 12 (1999) 71-83
23. Balk E., Tatsioni A., Lichtenstein A., Lau J., and Pittas A.G. Effect of chromium supplementation on glucose metabolism and lipids: a systematic review of randomized controlled trials. Diabetes Care (May 22; 2007) [Epub ahead of print]
24. Martin J., Wang Z.O., Zhang X.H., Wachtel D., Volaufova J., Matthews D.E., and Cefalu W.T. Chromium picolinate supplementation attenuates body weight gain and increases insulin sensitivity in subjects with type 2 diabetes. Diabetes Care 29 (2006) 1826-1832
25. Albarracin C.A., Fuqua B.C., Evans J.L., and Goldfine I.D. Chromium picolinate and biotin combination improves glucose metabolism in treated, uncontrolled overweight to obese patients with type 2 diabetes. Diabetes Metab. Res. Rev. (May 16; 2007) [Epub ahead of print]
26. Kleefstra N., Houweling S.T., Jansman F.G., Groenier K.H., Gans R.O., Meyboom-de Jong B., Bakker S.J., and Bilo H.J. Chromium treatment has no effect in patients with poorly controlled, insulin-treated type 2 diabetes in an obese Western population: a randomized, double-blind, placebo-controlled trial. Diabetes Care 29 (2006) 521-525